Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Rating of “Buy” by Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have covered the stock in the last year is $131.86.

A number of research firms have recently commented on LNTH. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. Truist Financial reissued a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, JMP Securities reissued a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Signaturefd LLC increased its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the period. State of New Jersey Common Pension Fund D boosted its position in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after purchasing an additional 115 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares in the last quarter. Bleakley Financial Group LLC boosted its position in shares of Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after purchasing an additional 129 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ:LNTH opened at $88.71 on Friday. Lantheus has a fifty-two week low of $53.47 and a fifty-two week high of $126.89. The company has a market cap of $6.17 billion, a price-to-earnings ratio of 14.76 and a beta of 0.44. The stock has a fifty day moving average price of $92.09 and a 200-day moving average price of $99.04.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.